Carta
Acesso aberto
Revisado por pares
Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation
2020; Springer Nature; Volume: 34; Issue: 7 Linguagem: Inglês
10.1038/s41375-020-0898-6
ISSN1476-5551
AutoresFlorian H. Heidel, Andreas Hochhaus,
Tópico(s)Inflammasome and immune disorders
Referência(s)